CICC raised HUTCHMED's target price 7.7 percent to HK$28 and Citi lifted its target to HK$39 after the biotech signed a licensing deal with GSK for HMPL-A830 worth up to $1.295 billion. The agreement includes a $110 million upfront payment and up to $1.185 billion in milestones for a preclinical cancer candidate.
Two brokers lifted their price targets on HUTCHMED within days of the biotech's landmark licensing agreement with GSK, with CICC moving its target up 7.7 percent to HK$28 and Citi raising its to HK$39 from HK$36.
CICC maintained its Outperform rating on the Hong Kong-listed drugmaker, citing the deal's effect on revenue recognition timing. The broker raised its 2026 net profit forecast 41 percent to $78.07 million but cut its 2027 estimate 25 percent to $66.38 million, reflecting when milestone payments land under the agreement.
HUTCHMED granted GSK exclusive rights to develop and commercialize HMPL-A830, an antibody-targeted therapy conjugate for KRAS-mutant cancers, everywhere except mainland China, Hong Kong, Macau and Taiwan. The deal includes up to $1.185 billion in development, regulatory and commercial milestones plus tiered royalties on net sales. The global Phase I program is expected to begin in the second half of 2026, with HUTCHMED running the trial and GSK taking over subsequent development and commercialization.
Shares of HUTCHMED jumped 11.6 percent to HK$21.36 on Sept. 3, the day the deal was announced, while the AIM listing gained about 17 percent. Citi's HK$39 target implies roughly 73 percent upside from the stock's recent level near HK$22.60.
The agreement marks the first hard market price on HUTCHMED's ATTC platform, which has three assets in development. GSK also secured a right of first negotiation on a second, earlier-stage ATTC candidate. HUTCHMED's first-half 2026 revenue was $278.3 million, essentially flat year over year, with net income attributable to shareholders of $15.9 million.
The $110 million upfront exceeds the $40.9 million HUTCHMED booked across its entire "other oncology and immunology" licensing line in the first half of 2026 and is more than double the half-year revenue of ELUNATE, its top-selling drug in China. The company guided full-year 2026 oncology and immunology revenue to $330 million to $450 million.
GSK's global head of oncology R&D, Hesham Abdullah, said the dual KRAS-EGFR mechanism "has the potential to significantly improve upon current standard of care." The deal follows GSK's $500 million upfront agreement with Jiangsu Hengrui Pharma in July 2025 for a package of up to 12 candidates that could reach $12.5 billion.
The broker upgrades reflect growing institutional confidence in HUTCHMED's pipeline value, though the stock still trades well below both new targets. Investors will watch the Phase I trial initiation for HMPL-A830 in the coming months as the next test of the platform's promise.
This article is for informational purposes only and does not constitute investment advice.
